

Intermediary licenses have been reissued by the Federal Maritime Commission pursuant to section 19 of the Shipping Act of 1984, as amended

by the Ocean Shipping Reform Act of 1998 (46 U.S.C. app. 1718) and the regulations of the Commission pertaining to the licensing of Ocean

Transportation Intermediaries, 46 CFR 515.

License No.	Name/address	Date reissued
4055N .....	International Cargo Services, Inc., 139 Mitchell Avenue, Suite #106, South San Francisco, CA 94080.	December 31, 2000.
18F .....	International Transportation Corp., 17 Battery Place, Suite 928, New York, NY 10004 .....	June 10, 1999.
4577F .....	Transtar Shipping, Inc., 405 Victory Avenue, Suite D, South San Francisco, CA 94080 .....	January 1, 2001.

**Sandra L. Kusumoto,**  
 Director, Bureau of Consumer Complaints and Licensing.  
 [FR Doc. 01-3766 Filed 2-13-01; 8:45 am]  
**BILLING CODE 6730-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Office of the Secretary**

**Agency Information Collection Activities: Submission for OMB Review; Comment Request**

The Department of Health and Human Services, Office of the Secretary publishes a list of information collections it has submitted to the Office of Management and Budget (OMB) for clearance in compliance with the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35) and 5 CFR 1320.5. The following are those information collections recently submitted to OMB.

1. *Office of Research Integrity Educational Program: A Needs Assessment—NEW*—The Office of Research Integrity (ORI) is proposing a survey of officials of research institutions to collect information on training needs in the areas of the promotion of research integrity and the prevention of scientific misconduct. The results of this survey will be used to develop a strategic plan for the ORI educational program which will be consistent with the recent organizational change requiring ORI to place greater emphasis on education and prevention. *Respondents:* Research Institutions; *Number of Respondents:* 500; *Burden per Response:* 10 minutes; *Total Burden:* 84 hours.

*OMB Desk Officer:* Allison Eydt.  
 Copies of the information collection packages listed above can be obtained by calling the OS Reports Clearance Officer on (202) 690-6207. Written comments and recommendations for the proposed information collection should be sent directly to the OMB desk officer designated above at the following address: Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, 725 17th Street NW., Washington, DC 20503.

Comments may also be sent to Cynthia Agens Bauer, OS Reports Clearance Officer, Room 503H, Humphrey Building, 200 Independence Avenue SW., Washington DC, 20201.

Written comments should be received within 30 days of this notice.

Dated: January 29, 2001.

**Kerry Weems**  
 Acting Deputy Assistant Secretary, Budget.  
 [FR Doc. 01-3737 Filed 2-13-01; 8:45 am]  
**BILLING CODE 4150-31-M**

**FEDERAL RESERVE SYSTEM**

**Sunshine Act Meeting**

*Agency Holding the Meeting:* Board of Governors of the Federal Reserve System.

*Time and Date:* 11:00 a.m., Tuesday, February 20, 2001.

*Place:* Marriner S. Eccles Federal Reserve Board Building, 20th and C Streets, NW., Washington, DC 20551.

*Status:* Closed.

*Matters to be Considered:*

1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.

2. Any items carried forward from a previously announced meeting.

*Contact Person for More Information:* Lynn S. Fox, Assistant to the Board; 202-452-3204.

**SUPPLEMENTARY INFORMATION:** You may call 202-452-3206 beginning at approximately 5 p.m. two business days before the meeting for a recorded announcement of bank and bank holding company applications scheduled for the meeting; or you may contact the Board's Web site at <http://www.federalreserve.gov> for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

Dated: February 9, 2001.

**Robert deV. Frierson,**  
 Associate Secretary of the Board.  
 [FR Doc. 01-3814 Filed 2-9-01; 4:49 pm]  
**BILLING CODE 6210-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

*Name of Committee:* Peripheral and Central Nervous System Drugs Advisory Committee.

*General Function of the Committee:* To provide advice and recommendations to the agency on FDA's regulatory issues.

*Date and Time:* The meeting will be held on March 13, 14, and 15, 2001, 8 a.m. to 5 p.m.

*Location:* Holiday Inn, The Ballroom, Two Montgomery Village Ave., Gaithersburg, MD.

*Contact:* Sandra L. Titus or Lauren W. Parcover, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301-827-7001, or e-mail: [Tituss@cder.fda.gov](mailto:Tituss@cder.fda.gov), or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area) code 12543. Please call the Information Line for up-to-date information on this meeting.

*Agenda:* On March 13, 2001, the committee will discuss drug development for individuals with mild cognitive impairment (MCI). In the

recent literature there has been a discussion of an entity referred to as MCI. While MCI is considered by some to be a distinct clinical entity, others consider that the majority of patients diagnosed with MCI have an early form of Alzheimer's Disease. It is critical for regulatory purposes that the issues surrounding this diagnosis are fully explored. Toward that end the committee will listen to speakers and discuss the following and other related questions:

1. Can MCI be clearly defined in a clinical setting?
2. Are there valid criteria for the diagnosis of MCI?
3. Can MCI be distinguished from Alzheimer's Disease and other causes of dementia?
4. What outcome measures are appropriate to use in clinical drug trials conducted in MCI?
5. Should clinical drug trials in MCI incorporate any special features in their design?

On March 14, 2001, the committee will discuss drug development for individuals with vascular dementia. While vascular dementia is considered by some to be a distinct entity others do not agree that it can be easily distinguished from Alzheimer's Disease and/or other dementias. It is critical for regulatory purposes that the issues surrounding this diagnosis are fully explored. Toward that end the committee will listen to presentations and then discuss the following and other related questions:

1. Can vascular dementia be clearly defined in a clinical setting?
2. Are there valid criteria for the diagnosis of vascular dementia?
3. Can vascular dementia be distinguished from Alzheimer's Disease and other causes of dementia?
4. What outcome measures are appropriate to use in clinical drug trials conducted in vascular dementia?
5. Should clinical drug trials in vascular dementia incorporate any special features in their design?

FDA will provide a background position paper on MCI and on vascular dementia prior to each meeting. When the background material becomes available, it will be posted under the Peripheral and Central Nervous Systems Drugs Advisory Committee Docket site at <http://www.fda.gov/ohrms/dockets/ac/acmenu.htm>. (Click on the year 2001 and scroll down to the Peripheral and Central Nervous Systems Drugs meetings.)

On March 15, 2001, the committee will consider the safety and efficacy of

new drug application (NDA) 21-196, Xyrem® (sodium oxybate, Orphan Medical, Inc.), proposed to reduce the incidence of cataplexy and to improve the symptom of daytime sleepiness for persons with narcolepsy. A main focus of the deliberations will be on risk management issues.

*Procedure:* Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by March 1, 2001. On March 13 and 14, 2001, oral presentations from the public will be scheduled between approximately 10:30 a.m. and 12:30 p.m. Time allotted for each presentation may be limited. On March 15, 2001, oral presentations from the public will be scheduled between approximately 1 p.m. and 1:30 p.m. Those desiring to make formal oral presentations should notify the contact person before March 1, 2001, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: February 6, 2001.

**Linda A. Suydam,**

*Senior Associate Commissioner.*

[FR Doc. 01-3665 Filed 2-13-01; 8:45 am]

**BILLING CODE 4160-01-S**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Office of Inspector General**

**Program Exclusions: January 2001**

**AGENCY:** Office of Inspector General, HHS.

**ACTION:** Notice of program exclusions.

During the month of January 2001, the HHS Office of Inspector General imposed exclusions in the cases set forth below. When an exclusion is imposed, no program payment is made to anyone for any items or services (other than an emergency item or service not provided in a hospital emergency room) furnished, ordered or prescribed by an excluded party under the Medicare, Medicaid, and all Federal Health Care programs. In addition, no program payment is made to any business or facility, e.g., a hospital, that submits bills for payment for items or services provided by an excluded party. Program beneficiaries remain free to

decide for themselves whether they will continue to use the services of an excluded party even though no program payments will be made for items and services provided by that excluded party. The exclusions have national effect and also apply to all Executive Branch procurement and non-procurement programs and activities.

Subject city, state	Effective date
<b>PROGRAM-RELATED CONVICTIONS</b>	
AHMED, ASHFAQ .....	02/20/2001
BROWNSTOWN TWP, MI	
BIAGGI, BART .....	02/20/2001
SAN JOSE, CA	
BINDER, MARK ALBERT .....	02/20/2001
UTICA, NY	
BISLAMIAN, ARTHUR	
SAMVEL .....	02/20/2001
LOS ANGELES, CA	
BODISON, LARRY L	
WALTERBORO, SC	
CENTRAL AMBULANCE	
SERVICE, INC .....	02/20/2001
CORAOPOLIS, PA	
CHIN, JENNY .....	02/20/2001
LONG BEACH, CA	
CRAWFORD, CAROLYN .....	02/20/2001
PICKENS, MS	
D'AMATO, JAMES .....	02/20/2001
W BABYLON, NY	
DONNELLY, BARBARA J .....	02/20/2001
CINCINNATI, OH	
ELLENWOOD, JANET L .....	02/20/2001
NAVARRA, OH	
FELEKIAN, HRACH .....	02/20/2001
LONG BEACH, CA	
GALIANO, JORGE .....	02/20/2001
MIAMI, FL	
GOLDSTEIN, JOSEPH .....	02/20/2001
SCARSDALE, NY	
GOROSH, RICHARD P .....	02/20/2001
LANSING, MI	
GREATHOUSE, BETTY .....	02/20/2001
LARVED, KS	
GUIDOTTI-ALEXANDER,	
ELAINE .....	02/20/2001
SAN JOSE, CA	
IMPERIAL, NORMAN .....	02/20/2001
ANAHEIM, CA	
JOHNSON, DEROTT .....	02/20/2001
STURTEVANT, WI	
JOYNER, MELBA J .....	02/20/2001
WINTERVILLE, NC	
KURINETS, VLADIMIR .....	02/20/2001
BROOKLYN, NY	
LORENZO, LORENZO .....	02/20/2001
HIALEAH, FL	
MACDONALD, DANESSA	
MAICHELE .....	02/20/2001
PUNXSUTAWNEY, PA	
MATHIS, NELSON D .....	02/20/2001
HENDERSONVILLE, NC	
MATO, AMPARO .....	02/20/2001
HIALEAH, FL	
MATO, ADOLFO .....	02/20/2001
HIALEAH, FL	
NICKOLAOU, MARK LOUIS ....	02/20/2001
SAINT JOHN, IN	
NIKOGOSYAN, VARDAN .....	02/20/2001
LOS ANGELES, CA	
PATEL, NIRANJAN .....	02/20/2001